Seagen And Astellas Announced Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival In Patients Treated with PADCEV And KEYTRUDA In First-Line Advanced Bladder Cancer
Portfolio Pulse from Charles Gross
Seagen Inc. and Astellas Pharma Inc. announced positive results from the Phase 3 EV-302 clinical trial for PADCEV in combination with KEYTRUDA versus chemotherapy. The combination improved overall survival and progression-free survival in patients with previously untreated locally advanced or metastatic urothelial cancer. The risk of death was reduced by 53% and overall survival improved by more than 15 months compared to chemotherapy. These results will form the basis of global regulatory submissions.
October 22, 2023 | 2:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Astellas Pharma's successful trial results for PADCEV in combination with KEYTRUDA could potentially boost its stock in the short term.
Positive clinical trial results often lead to an increase in a company's stock price as it indicates potential future revenue from the successful product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Seagen's successful trial results for PADCEV in combination with KEYTRUDA could potentially boost its stock in the short term.
Positive clinical trial results often lead to an increase in a company's stock price as it indicates potential future revenue from the successful product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100